Home >> News >> Business >> Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022

Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022

The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from 2016 to 2022.

The purpose of the report is to illustrate the state of the market of Irritable Bowel Syndrome With Diarrhea Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.

Browse here for full report: https://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market

Market Insights

IBS affects between 10% to 20% individuals in the developed countries. Since the underlying cause of IBD remains unknown, the treatment market for the same is observed to be unvisited and is characterized by very few indicated drugs. By far, alosetron has been the only drug approved for IBS-D treatment. With the approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the IBS-D treatment market have opened, giving hopes to the patients.

Both Viberzi and Xifaxan are determined to be safe, Viberzi may receive controlled substance label due to risk of potential abuse. Viberzi and other IBS-D drugs act on opioid receptors, thus it is a mu receptor antagonist and kappa receptor antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since it acts by altering the bacterial flora in the guts.
Xifaxan has been reportedly prescribed off label for treating IBS-D. Its formal sanction will thus support the growth in demand for the drug in the forecast period. Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further additional 1 week dosage if the need arises. However, its long term role in efficiently containing IBS-D is still questioned. Viberzi, on the other hand, easily fits the profile of everyday medication for chronic disease treatment, similar to diabetes and CVD treatments. Further safety and effective assessments on these drugs are lined up, which will clear the market status of the two drugs.

The market for Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D affects over 15 million Americans, with no single drugs having a clear domination in the market. Loperamide, angidepressants, alosetron, bile acid binders and similar such drugs were the standard treatments in the past. Medical professionals have largely relied on trial and error approach for treating IBS-D patients.

Why was the report written?

This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Irritable Bowel Syndrome With Diarrhea Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.

What is the current market landscape and what is changing?

Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.

The report on the market of Irritable Bowel Syndrome With Diarrhea Drugs contains:

Analysis and forecast of Irritable Bowel Syndrome With Diarrhea Drugs market dynamics;

Analysis of domestic production, market shares of the main market players;

Analysis of exports and imports;

Analysis of factors, leading the development of the Irritable Bowel Syndrome With Diarrhea Drugs market;

Assessment and forecast of Irritable Bowel Syndrome With Diarrhea Drugs market development;

Financial and business profiles of the leading companies in the Irritable Bowel Syndrome With Diarrhea Drugs industry.

Scope

– Up to date working Irritable Bowel Syndrome With Diarrhea Drugs data by major regions in the world, the forecast of planned capacity additions by 2026

– The annual breakdown of capital expenditure spending on proposed Irritable Bowel Syndrome With Diarrhea Drugs for the period 2018 to 2026

– Planned Irritable Bowel Syndrome With Diarrhea Drugs additions and capital expenditure spending by key countries and companies across the world

– Planned capital expenditure spending on new Irritable Bowel Syndrome With Diarrhea Drugs projects by region, key countries, and companies

– Details of major planned Irritable Bowel Syndrome With Diarrhea Drugs projects in the world up to 2026

Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/57736

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Toll Free (US/CANADA): +1-800-361-8290

Web: https://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *